Legend Biotech Corporation (LEGN) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

First analysis of CARTITUDE-2 Cohort D study investigating CARVYKTI® in multiple myeloma with suboptimal response after front-line ASCT featured...

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

First disclosure from Cohort D of the Phase 2 CARTITUDE-2 study investigating CARVYKTI® in patients who had suboptimal response to frontline...

U.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed Reactions

U.S. index futures show an upward trend in Monday’s pre-market following the best week of the year for...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $157 million EC and US FDA approved CARVYKTI® label expansion...

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation...

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am...

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse Legend Biotech Corporation...

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social...